

## Appendix A. Searching Strategy

Pubmed. Total articles: 656

|    |                                                    |
|----|----------------------------------------------------|
| 1  | Ankle                                              |
| 2  | Talocrural                                         |
| 3  | Talo-crural                                        |
| 4  | Talocalcaneal                                      |
| 5  | Talo-calcaneal                                     |
| 6  | Talofibular                                        |
| 7  | Talo-fibular                                       |
| 8  | Ligament                                           |
| 9  | Lateral Ligament ankle                             |
| 10 | Medial Ligament ankle                              |
| 11 | 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR<br>8 OR 9 OR 10 |
| 12 | Sprain                                             |
| 13 | Strain                                             |
| 14 | Ankle injur*                                       |
| 15 | Ankle sprain                                       |
| 16 | Inversion sprain                                   |
| 17 | Eversion sprain                                    |
| 18 | 12 OR 13 OR 14 OR 15 OR 16 OR 17                   |
| 19 | 11 AND 18                                          |
| 20 | Conservat* treat*                                  |
| 21 | Conservative management                            |
| 22 | Non-surgical treatment                             |
| 23 | CAST                                               |
| 24 | Rehabilitation program                             |
| 25 | Myofascial                                         |
| 26 | Conservative program                               |
| 27 | Manual Therapy                                     |
| 28 | Physiotherapeutic intervention                     |
| 29 | Bandage                                            |
| 30 | Plaster                                            |
| 31 | Exercise programme                                 |

|    |                                                                                                          |
|----|----------------------------------------------------------------------------------------------------------|
| 32 | Home exercise                                                                                            |
| 33 | RICE                                                                                                     |
| 34 | Taping                                                                                                   |
| 35 | TENSE                                                                                                    |
| 36 | Ultrasound                                                                                               |
| 37 | 20 OR 21 OR 22 OR 23 OR 24 OR 25<br>OR 26 OR 27 OR 28 OR 29 OR 30 OR<br>31 OR 32 OR 33 OR 34 OR 35 OR 36 |
| 38 | 19 AND 37                                                                                                |

CINAHL. Total articles: 2176

|    |                         |
|----|-------------------------|
| 1  | Ankle Sprains           |
| 2  | Inversion Sprain        |
| 3  | Eversion Sprain         |
| 4  | Ankle Injury            |
| 5  | 1 OR 2 OR 3 OR 4        |
| 6  | Conservative treatment  |
| 7  | Conservative management |
| 8  | Rehabilitation programs |
| 9  | Bandage                 |
| 10 | Physiotherapeutic       |
| 11 | 6 OR 7 OR 8 OR 9 OR 10  |
| 12 | 5 AND 11                |

SCOPUS. Total articles: 597

|   |                                         |
|---|-----------------------------------------|
| 1 | TITLE-ABS-KEY (Ankle Sprain)            |
| 2 | TITLE-ABS-KEY (Inversion Sprain)        |
| 3 | TITLE-ABS-KEY (Eversion Sprain)         |
| 4 | TITLE-ABS-KEY (Ankle Injury)            |
| 5 | 1 OR 2 OR 3 OR 4                        |
| 6 | TITLE-ABS-KEY (Conservat* treat*)       |
| 7 | TITLE-ABS-KEY (Conservative management) |
| 8 | TITLE-ABS-KEY (TENSE)                   |

|    |                                        |
|----|----------------------------------------|
| 9  | TITLE-ABS-KEY (Bandage)                |
| 10 | TITLE-ABS-KEY (Rehabilitation program) |
| 11 | TITLE-ABS-KEY (Physiotherapeutic)      |
| 12 | 6 OR 7 OR 8 OR 9 OR 10 OR 11           |
| 13 | 5 AND 12                               |

SPORTSDiscus via EBSCOHost. Total articles: 5618

|    |                         |
|----|-------------------------|
| 1  | Ankle Sprains           |
| 2  | Inversion Sprain        |
| 3  | Eversion Sprain         |
| 4  | Ankle injury            |
| 5  | 1OR 2 OR 3 OR 4         |
| 6  | Conservative treatment  |
| 7  | Conservative management |
| 8  | Rehabilitation program  |
| 9  | Physiotherapeutic       |
| 10 | 6OR 7 OR 8 OR 9 OR 10   |
| 11 | 5 AND 10                |

PsycINFO. Total articles: 1371

|    |                         |
|----|-------------------------|
| 1  | Ankle Sprains           |
| 2  | Inversion Ankle sprain  |
| 3  | Eversion Ankle sprain   |
| 4  | 1 OR 2 OR 3             |
| 5  | Conservative treatment  |
| 6  | Conservative management |
| 7  | Rehabilitation program  |
| 8  | Physiotherapeutic       |
| 9  | 5 OR 6 OR 7 OR 8        |
| 10 | 4 AND 9                 |

PROSPERO. Total articles: 38

|   |               |
|---|---------------|
| 1 | Ankle Sprains |
|---|---------------|

Appendix B. Table 1. Characteristics of the studies included in the review

| Author<br>Year Country                             | Patients<br>(n) | Age (years)                                                        | Sex                               |                                   | Type of RCT<br>design                                                    | Type of sprain                                                         | Type of treatment                                                                                                                                                | Follow<br>up | Outcome                                                                                                 |
|----------------------------------------------------|-----------------|--------------------------------------------------------------------|-----------------------------------|-----------------------------------|--------------------------------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------------------------------------------------------------------------------------------------|
|                                                    |                 |                                                                    | Female                            | Male                              |                                                                          |                                                                        |                                                                                                                                                                  |              |                                                                                                         |
| Pellow JE et al.<br>2001[24].<br>South Africa      | 30              | 15-50<br>Total mean<br>age: 24.9<br>Group 1: 23.7<br>Group 2: 26.1 | 11<br>Group 1: 9<br>Group 2: 2    | 19<br>Group 1: 6<br>Group 2: 13   | Single-blind,<br>comparative,<br>controlled study                        | Subacute ankle<br>inversion sprains<br>(<48h after initial<br>injury)  | Mortise separation adjustment, group 1<br>(n=15)<br>Detuned ultrasound machine, group 2<br>(n=15)                                                                | 28 days      | McGill Pain Questionnaire<br>Numerical Pain Rating<br>Scale 101                                         |
| Kucera et al. 2004<br>[25]. Prague                 | 203             | 18-50<br>Group 1: 27.7<br>Group 2: 28.3                            | 78<br>Group 1: 38<br>Group 2: 40  | 125<br>Group 1: 66<br>Group 2: 59 | Randomised,<br>double-blind<br>clinical<br>multicentre<br>parallel study | Acute lateral ankle<br>distortions (24h<br>after the injury)           | Verum, Group 1: Cream 10%<br>Reference, Group 2: Cream 1%                                                                                                        | 14 days      | VAS-10                                                                                                  |
| Truyols-Dominguez<br>S. et al. 2013 [26].<br>Spain | 50              | 28-38<br>Total mean<br>age: 33                                     | 13<br>Group 1: 6<br>Group 2: 7    | 37<br>Group 1: 19<br>Group 2: 18  | Randomised<br>clinical trial                                             | Acute inversion<br>ankle sprain<br>Grade I and II<br>(Injured <5 days) | Thrust and nonthrust manipulation and<br>exercise intervention, group 1 (n=25)<br>The same protocol plus myofascial manual<br>therapy techniques, group 2 (n=25) | 28 days      | Numeric pain rating scale<br>Total Functional Score for<br>Assessment of Acute<br>Lateral Ankle Sprains |
| Bleakley et al.<br>2006[27]. UK                    | 89              | Total mean<br>age: 29.9<br>Group 1: 29.8<br>Group 2: 31.2          | 31<br>Group 1: 15<br>Group 2: 16  | 58<br>Group 1: 28<br>Group 2: 30  | Randomised<br>controlled trial,<br>double-blind                          | Mild/moderate<br>ankle sprain<br><48h after injury)<br>Grades I and II | Intermittent ice, group 1 (n=43)<br>Standard ice application, group 2 (n=46)                                                                                     | 42 days      | Binskley's lower extremity<br>functional scale<br>VAS                                                   |
| Cooke et al. 2009<br>[28]. UK                      | 584             | 16-72<br>Total mean<br>age: 30                                     | 247<br>Group 1: 64<br>Group 2: 54 | 337<br>Group 1: 80<br>Group 2: 88 | Multicentred<br>RCT with<br>blinded                                      | Acute severe ankle<br>sprain                                           | Group 1: Tubular bandage (n=144)<br>Group 2: Below-knee cast (n=142)<br>Group 3: Aircast brace (n=149)                                                           | 270 days     | FAOS<br>Functional Limitations<br>Profile                                                               |

|                                       |     |                                                          |                                   |                                     |                                                       |                                                      |                                                                                           |          |                                                       |
|---------------------------------------|-----|----------------------------------------------------------|-----------------------------------|-------------------------------------|-------------------------------------------------------|------------------------------------------------------|-------------------------------------------------------------------------------------------|----------|-------------------------------------------------------|
|                                       |     | Group 1: 31<br>Group 2: 30<br>Group 3: 29<br>Group 4: 30 | Group 3: 65<br>Group 4: 64        | Group 3: 84<br>Group 4: 85          | assessment of outcome                                 |                                                      | Group 4: Bledsoe boot (n=149)                                                             |          | SF-12<br>EQ-5D<br>VAS                                 |
| Bassett et al. 2007 [11]. New Zealand | 47  | 13-62                                                    | 19<br>Group 1: 11<br>Group 2: 8   | 28<br>Group 1: 14<br>Group 2: 14    | Controlled trial                                      | Acute ankle sprain (first-time) Grades I, II and III | Clinical intervention, group 1 (n=25)<br>Home intervention, group 2 (n=22)                | 14 days  | Lower Limb Task Questionnaire<br>Motor Activity Scale |
| Bleakley et al. 2010 [289]. UK        | 101 | 16-65                                                    | 32<br>Group1: 17<br>Group2: 15    | 69<br>Group1: 34<br>Group 2: 35     | Randomised controlled trial, blinded outcome assessor | Acute ankle sprain Grade I or II                     | Standard, group 1 (n=51)<br>Exercise, group 2 (n=50)                                      | 112 days | VAS<br>LEFS                                           |
| Brison et al. 2016 [9]. Canada        | 504 | -                                                        | 280<br>Group1: 146<br>Group2: 134 | 224<br>Group 1: 108<br>Group 2: 116 | Randomised controlled trial                           | Simple Grade I or II ankle sprain.                   | Physiotherapy, group 1 (n=254)<br>Usual care, group 2 (n=250)                             | 180 days | Foot and Ankle Outcome Score                          |
| Cleland et al. 2013 [2930]. USA       | 74  | 16-60                                                    | 36<br>Group 1: 19<br>Group 2: 17  | 38<br>Group 1: 18<br>Group 2: 20    | Randomised clinical trial, non-blinded                | Inversion ankle sprain, acute and subacute           | Manual therapy and exercise, group 1 (n=37)<br>Home exercise programme, group 2 (n=37)    | 180 days | FAAM<br>LEFS<br>Numeric pain rating scale             |
| Coudreuse et al. 2010 [304]. France   | 233 | 18-65                                                    | 86                                | 148                                 | Randomised, double-blind, placebo-controlled study    | Lateral ankle sprain (<48 hours after the injury)    | Novel plaster with diclofenac, epolamine and heparin, group 1<br>Placebo plaster, group 2 | 7 days   | VAS                                                   |

|                                          |     |                                                               |                                                    |                                                     |                                                              |                                                                          |                                                                                                                                                      |         |                                                                           |
|------------------------------------------|-----|---------------------------------------------------------------|----------------------------------------------------|-----------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|---------|---------------------------------------------------------------------------|
| Fotiadis et al. 2011<br>[312]. Greece    | 79  | Mean age<br>Group 1: 38.21<br>Group 2: 35.35                  | 35<br>Group 1: 20<br>Group 2: 15                   | 44<br>Group 1: 22<br>Group 2: 24                    | Prospective randomised study                                 | Type II and III acute (less than 24h) lateral ankle sprain               | Group 1: Micronized purified flavonoid fraction (Daflon 1,000 mg) (n = 42)<br>Group 2: (Control group) Standard treatment (n = 39)                   | 20 days | VAS                                                                       |
| Gonzalez de Vega et al. 2013 [10]. Spain | 420 | 18-40<br>Group 1: 39<br>Group 2: 39<br>Group 3: 34            | 112<br>Group 1: 39<br>Group 2: 101<br>Group 3: 103 | 308<br>Group 1: 104<br>Group 2: 101<br>Group 3: 103 | Multicentre, randomised, blinded and active-controlled study | Acute unilateral ankle sprain within the past 24 h. Grades I, II and III | Traumeel ointment (T-O), group 1 (n = 143)<br>Traumeel gel (T-G), group 2 (n = 140)<br>Diclofenac gel, group 3 (n = 137)                             | 42 days | VAS<br>FAAM                                                               |
| Man et al. 2007 [323]. UK                | 34  | Total mean age 30.2<br>Group 1 34<br>Group 2 29<br>Group 3 28 | 11                                                 | 23                                                  | Randomised trial                                             | Acute ankle sprain injury (within 5 days)                                | Neuromuscular electrical stimulation treatment, group 1 (n = 11)<br>Submotor ES treatment (control group), group 2 (n=11)<br>Sham ES, group 3 (n=12) | 14 days | Adapted Hughston Clinic Subjective Rating Scale for Ankle Disorders score |
| Kim et al. 2017[334]. South Korea        | 22  | Total mean age: 17.72                                         | 0                                                  | 22                                                  | Cross-over randomised design                                 | Grades I and II lateral ankle sprain                                     | Ankle balance taping group 1<br>Placebo taping group 2<br>No taping group 3                                                                          | 28 days | VAS                                                                       |
| Naeem et al. 2014. [345]. Pakistan       | 120 | Group 1: 28.77<br>Group 2: 29.83                              | 77<br>Group 1: 35<br>Group 2: 42                   | 43<br>Group 1: 25<br>Group 2: 18                    | Level I Randomised controlled trial                          | Grade I or II lateral ankle sprain                                       | Functional treatment tubigrip, group 1 (n=60)<br>Plaster of Paris, group 2 (n = 60)                                                                  | 42 days | VAS<br>Karlsson score                                                     |
| Sandoval et al. 2010 [356]. Colombia     | 28  | Total mean age: 21<br>Group 1: 21.3<br>Group 2: 22.5          | 10                                                 | 18                                                  | Double-blind, controlled clinical trial                      | Grade I and II sprain mild or moderate, non-severe                       | Conventional treatment, group 1 (n=10)<br>HVPC (+) group 2.<br>Conventional treatment and HVPC (positive polarity) (n = 8)                           | 56 days | VAS                                                                       |

|                                                  |    |                                                          |                                              |                                                |                                                                        |                                                                                          |                                                                                                                                                                                                 |         |                                                              |
|--------------------------------------------------|----|----------------------------------------------------------|----------------------------------------------|------------------------------------------------|------------------------------------------------------------------------|------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|--------------------------------------------------------------|
|                                                  |    | Group 3: 20.3                                            |                                              |                                                |                                                                        |                                                                                          | HVPC (-) group 3.<br>Conventional treatment and HVPC<br>(negative polarity) (n = 10)                                                                                                            |         |                                                              |
| Stasinopoulos et al.<br>2016 [367]. Greece.      | 50 | 18-35<br>Group 1: 27.92<br>Group 2: 27.96                | 15<br>Group 1: 8<br>Group 2: 7               | 35<br>Group 1: 19<br>Group 2: 16               | Single-centre,<br>parallel group,<br>single-blind,<br>controlled study | Acute ankle sprain<br>Grade II                                                           | Group 1: Cryotherapy plus Bioptron light<br>therapy (n = 27)<br>Group 2: Control group, cryotherapy only<br>(n = 23)                                                                            | 5 days  | VAS                                                          |
| Sultan et al. 2012<br>[378]. England             | 36 | Group 1: 30<br>Group 2: 34                               | -                                            | -                                              | Single-centre,<br>randomised,<br>single-blinded,<br>clinical trial     | Ankle sprains<br>sustained within 72<br>h. Grade I, II, III.                             | Tubigrip, group 1 (n=18)<br>Elastic stocking, group 2 (n=18)                                                                                                                                    | 56 days | VAS<br>SF12                                                  |
| Tully et al. 2012<br>[389]. Northern<br>Ireland. | 52 | 16-65<br>Group 1: 24.1<br>Group 2: 26.1<br>Group 3: 21.9 | 23<br>Group 1: 6<br>Group 2: 8<br>Group 3: 9 | 29<br>Group 1: 10<br>Group 2: 10<br>Group 3: 9 | Randomised<br>controlled trial                                         | Acute ankle sprain<br>(<7 days)<br>Grade I or II                                         | Standard, group 1 (n=16)<br>Exercise, group 2 (n=18)<br>Non-injured control, Group 3 (n=18)                                                                                                     | 7 days  | Lower Extremity<br>Functional Scale<br>VAS                   |
| Zhao et al. 2018<br>[4039]. China.               | 62 | Group 1: 34<br>Group 2: 30<br>Group3: 33                 | -                                            | -                                              | Randomised<br>controlled trial                                         | Acute ankle sprains<br>identified at 48<br>hours since the<br>injury.<br>Grades I and II | Standard treatment (RICE), group 1 (n = 19)<br>Standard treatment (RICE) plus<br>acupressure therapy, group 2 (n = 21)<br>Standard treatment plus mock acupressure<br>therapy, group 3 (n = 22) | 56 days | VAS<br>American Orthopedic Foot<br>and Ankle Score<br>SF12v2 |

RCT: Randomised control trial; VAS: Visual Analogue Scale; FAOS: Foot and Ankle Outcome Score; SF-12: Short Form-12; EQ-5D: EuroQol-5D;

LEFS: Lower Extremity Functional Scale; FAAM: Foot and Ankle Ability Measure.

Appendix C. Table 2. Reported outcomes for pain relief and recovery of functional capacity

| Author                          | Outcome                        | Treatment                                         |          |                      |          |                                           |          |                            |          |  |  |  |  |
|---------------------------------|--------------------------------|---------------------------------------------------|----------|----------------------|----------|-------------------------------------------|----------|----------------------------|----------|--|--|--|--|
| Pellow JE et al. [24]           |                                | Experimental group: Mortise separation adjustment |          |                      |          | Control group: Detuned ultrasound machine |          |                            |          |  |  |  |  |
|                                 |                                | Pre                                               |          | Post 1 month         |          | p-value                                   |          | Pre                        |          |  |  |  |  |
|                                 | McGill Pain Questionnaire      | 0.20                                              |          | 0.03                 |          | 0.42                                      |          | 0.24                       |          |  |  |  |  |
|                                 | NPRS (0-10)                    | 28.73                                             |          | 8.33                 |          | 0.72                                      |          | 30.73                      |          |  |  |  |  |
| Kucera et al.[25]               |                                | Cream 10%                                         |          |                      |          | Cream 1%                                  |          |                            |          |  |  |  |  |
|                                 |                                | Visit 3/4                                         |          | Visit 14             |          | Visit 3/4                                 |          | Visit 14                   |          |  |  |  |  |
|                                 | VAS-10 pain at rest (mm)       | 28.7 ± 17.1                                       |          | 43.9 ± 22.3 46       |          | 14.7 ± 13.5                               |          | 41.6 ± 21.1                |          |  |  |  |  |
|                                 | VAS-10 functional (mm)         | 28.7 ± 18.0                                       |          | 50.8 ± 18.9          |          | 18.1 ± 13.6                               |          | 48.1 ± 19.8                |          |  |  |  |  |
| Truyols-Dominguez S. et al.[26] |                                | Experimental Group                                |          |                      |          | Comparison Group                          |          |                            |          |  |  |  |  |
|                                 |                                | Pre-treatment                                     |          | Post-treatment       |          | Pre-treatment                             |          | Post-treatment             |          |  |  |  |  |
|                                 | NPRS (0-10)                    | 5.4 ± 2.0                                         |          | 2.1 ± 1.4            |          | 5.1 ± 1.0                                 |          | 3.2 ± 1.5                  |          |  |  |  |  |
|                                 | Total Functional Score         | 38.9 ± 8.8                                        |          | 78.6 ± 13.9          |          | 40.9 ± 18.0                               |          | 64.0 ± 17.8                |          |  |  |  |  |
| Bleakley et al.[27]             |                                | Intermittent ice group                            |          |                      |          | Standard ice application group            |          |                            |          |  |  |  |  |
|                                 | LEFS                           | 24.6 ± 1.96                                       |          |                      |          | 22.3 ± 2.23                               |          |                            |          |  |  |  |  |
|                                 | Pain intensity at rest (0-10)  | 1.0 ± 0.16                                        |          |                      |          | 1.7 ± 0.22                                |          |                            |          |  |  |  |  |
|                                 | Pain intensity activity (0-10) | 3.9 (0.28)                                        |          |                      |          | 4.7 (0.27)                                |          |                            |          |  |  |  |  |
| Cooke et al.[28]                |                                | Tubular bandage (mean)                            |          | Bledsoe (difference) |          | Aircast difference                        |          | Below-knee cast difference |          |  |  |  |  |
|                                 |                                | 4 weeks                                           | 9 months | 4 weeks              | 9 months | 4 weeks                                   | 9 months | 4 weeks                    | 9 months |  |  |  |  |
|                                 |                                | Score                                             | Score    | Score                | ES       | Score                                     | ES       | Score                      | ES       |  |  |  |  |
|                                 | FAOS pain                      | 62.3                                              | 81.1     | 0.6                  | 0.03     | 1.7                                       | 0.09     | 3.5                        | 0.19     |  |  |  |  |
|                                 | FAOS symptoms                  | 59.8                                              | 79.2     | -0.8                 | -0.04    | -1.1                                      | -0.06    | 2.2                        | 0.12     |  |  |  |  |

|                      |                            |                             |          |             |                                    |             |       |                           |                  |                         |       |      |       |      |       |  |  |  |  |
|----------------------|----------------------------|-----------------------------|----------|-------------|------------------------------------|-------------|-------|---------------------------|------------------|-------------------------|-------|------|-------|------|-------|--|--|--|--|
|                      | FAOS ADL                   | 82.3                        | 93.1     | -0.1        | -0.01                              | 0.1         | 0.01  | 0.6                       | 0.05             | 1.0                     | 0.10  | 3.0  | 0.24  | 1.2  | 0.12  |  |  |  |  |
|                      | FAOS sports                | 44.7                        | 76.8     | -0.3        | -0.01                              | 1.0         | 0.04  | 0.0                       | 0.00             | 0.8                     | 0.03  | 5.0  | 0.20  | 2.4  | 0.10  |  |  |  |  |
|                      | FAOS QoL                   | 43.0                        | 64.9     | 1.9         | 0.08                               | 4.0         | 0.15  | 4.9                       | 0.22             | 6.1                     | 0.24  | 5.9  | 0.26  | 6.3  | 0.24  |  |  |  |  |
|                      | FLP ambulatory             | 16.9                        | 6.3      | 0.1         | 0.01                               | -1.5        | -0.18 | -0.1                      | 0.00             | -2.2                    | -0.26 | -3.1 | -0.24 | -1.7 | -0.21 |  |  |  |  |
|                      | SF-12 physical             | 39.2                        | 49.7     | -1.3        | -0.16                              | 0.2         | 0.03  | -1.4                      | -0.17            | -0.1                    | -0.01 | 2.2  | 0.27  | 0.3  | 0.04  |  |  |  |  |
|                      | SF-12 mental               | 43.4                        | 47.7     | 1.0         | 0.10                               | 1.4         | 0.14  | 0.1                       | 0.01             | 1.8                     | 0.18  | -0.6 | -0.05 | 1.2  | 0.12  |  |  |  |  |
|                      | EQ-5D                      | 0.60                        | 0.73     | 0.03        | 0.14                               | 0.06        | 0.28  | 0.00                      | 0.02             | 0.05                    | 0.25  | 0.06 | 0.28  | 0.04 | 0.18  |  |  |  |  |
|                      | VAS pain at rest           | 19.2                        | 10.1     | -0.7        | -0.04                              | 0.7         | 0.05  | -0.7                      | -0.04            | -2.9                    | -0.19 | -4.8 | -0.27 | -0.8 | -0.05 |  |  |  |  |
| Bassett et al.[11]   |                            | Clinical intervention group |          |             |                                    |             |       |                           |                  | Home intervention group |       |      |       |      |       |  |  |  |  |
|                      |                            | Pre                         |          | Post        |                                    | Pre         |       | Post                      |                  |                         |       |      |       |      |       |  |  |  |  |
|                      | LLTQ recreational subscale | 27.92±11.36                 |          | 12.00±10.10 |                                    | 20.27±12.58 |       | 8.18±7.24                 |                  |                         |       |      |       |      |       |  |  |  |  |
|                      | LLTQ ADL subscale          | 13.72±11.29                 |          | 2.32±3.60   |                                    | 7.18±7.06   |       | 1.82±3.58                 |                  |                         |       |      |       |      |       |  |  |  |  |
|                      | Motor Activity Scale       | 1.20±2.00                   |          | 5.14±1.28   |                                    | 1.77±1.60   |       | 5.73±1.08                 |                  |                         |       |      |       |      |       |  |  |  |  |
| Bleakley et al.[289] |                            | Standard                    |          |             |                                    | Exercise    |       |                           |                  |                         |       |      |       |      |       |  |  |  |  |
|                      |                            | Score                       |          |             |                                    | Score       |       |                           |                  |                         |       |      |       |      |       |  |  |  |  |
|                      | Pain intensity at rest     | 1.7±0.22                    |          |             |                                    | 1.0±0.16    |       |                           |                  |                         |       |      |       |      |       |  |  |  |  |
|                      | Pain intensity on activity | 4.7±0.27                    |          |             |                                    | 3.9±0.28    |       |                           |                  |                         |       |      |       |      |       |  |  |  |  |
|                      | Subjective function (LEFS) | 22.3±2.23                   |          |             |                                    | 24.6±1.96   |       |                           |                  |                         |       |      |       |      |       |  |  |  |  |
| Brison et al.[9]     |                            | Physiotherapy group         |          |             | Usual care group                   |             |       |                           |                  |                         |       |      |       |      |       |  |  |  |  |
|                      |                            | 1 month                     | 6 months |             | 1 month                            | 6 months    |       | P-value 1 month           | P-value 6 months |                         |       |      |       |      |       |  |  |  |  |
|                      | FAOS                       | 23/180                      | 92/165   |             | 33/213                             | 113/174     |       | 0.65                      | 0.09             |                         |       |      |       |      |       |  |  |  |  |
| Cleland et al.[290]  |                            | Home Exercise Programme     |          |             | Manual Therapy and Exercise (MTEX) |             |       | Between-Group Differences |                  |                         |       |      |       |      |       |  |  |  |  |
|                      |                            | 4 weeks                     | 6 months |             | 4 weeks                            | 6 months    |       | 4 weeks                   | 6 months         |                         |       |      |       |      |       |  |  |  |  |

|                              |                                     |             |                              |             |                    |            |          |
|------------------------------|-------------------------------------|-------------|------------------------------|-------------|--------------------|------------|----------|
|                              | FAAM ADL (0%-100%)                  | 9.6         | 24.6                         | 21.3        | 30.8               | 11.7       | 6.2      |
|                              | FAAM sports (0%-100%)               | 13.8        | 33.5                         | 27.1        | 40.7               | 13.3       | 7.2      |
|                              | LEFS (0-80)                         | 5.6         | 17.3                         | 18.4        | 25.3               | 12.8       | 8.1      |
|                              | NPRS (0-10)                         | -1.5        | -3.1                         | -2.7        | -3.6               | -1.2       | -0.47    |
| Coudreuse et al.[340]        | DHEP group                          |             | Placebo group                |             | P-value            |            |          |
|                              | Baseline                            | 7 days      | Baseline                     | 7 days      | Baseline           | 7 days     |          |
|                              | VAS pain (0-100)                    | 73.2±1.0    |                              | 69.3±1.1    |                    | p=0.007    | p<0.01   |
| Fotiadis et al.[312]         | Daflon group                        |             | Control group                |             | P-value            |            |          |
|                              | 2 days                              | 20 days     | 2 days                       | 20 days     | 2 days             | 20 days    |          |
|                              | VAS pain (1-10)                     | 2.26 ± 1.86 | 0.64 ± 1.39                  | 2.0 ± 1.64  | 0.32 ± 0.57        | 0.625      | 0.908    |
| Gonzalez de Vega et al. [10] | Traumeel ointment                   |             | Traumeel gel                 |             | Diclofenac gel     |            |          |
|                              | Pre                                 | Post        | Pre                          | Post        | Pre                | Post       |          |
|                              | VAS ankle pain                      | 52.6        | 3.1                          | 53.1        | 4.1                | 55.7       | 3.1      |
|                              | FAAM ADL                            | 51.2        | 41.7                         | 56.0        | 40.5               | 51.2       | 41.7     |
|                              | FAAM Sports                         | 18.8        | 50.0                         | 25.0        | 50.0               | 18.8       | 50.0     |
| Man et al.[323]              | NMES Group                          |             | Submotor ES Group            |             | Sham ES Group      |            |          |
|                              | Session 1                           | Session 3   | Session 1                    | Session 3   | Session 1          | Session 3  |          |
|                              | Adapted HCSRSAD                     | 65 (13)     | 42 (20)                      | 70 (10)     | 45 (17)            | 63 (12)    | 46 (16)  |
| Kim et al.[334]              | Aquatic exercise                    |             | Land-based Exercise          |             | Interaction Effect |            |          |
|                              | Baseline                            | 4 weeks     | Baseline                     | 4 weeks     |                    |            |          |
|                              | VAS for pain                        | 5.70 (0.36) | 0.17 (0.16)                  | 5.66 (0.36) | 0.73 (0.16)        | F = 3.75   | P = .033 |
| Naeem et al.[345]            | Functional Treatment Tubigrip group |             | Plaster of Paris (POP) group |             | P-value            |            |          |
|                              | At presentation                     | At 6 weeks  | at presentation              | at 6 weeks  | At presentation    | At 6 weeks |          |

|                           |                        |                                      |               |                                 |                        |                                 |                  |
|---------------------------|------------------------|--------------------------------------|---------------|---------------------------------|------------------------|---------------------------------|------------------|
|                           | VAS                    | 8.40 ± 0.92                          | 3.88 ± 0.85   | 8.27 ± 0.94                     | 4.97 ± 0.82            | 0.434                           | <0.001           |
|                           | Karlsson score         | 21.17 ± 6.31                         | 76.25 ± 10.67 | 23.67 ± 5.24                    | 70.10 ± 6.35           | 0.571                           | <0.001           |
| Sandoval et al.[356]      |                        | Conventional treatment CC            |               | Conventional treatment EEAV (+) |                        | Conventional treatment EEAV (-) |                  |
|                           |                        | First                                | Last          | First                           | Last                   | First                           | Last             |
|                           | VAS at rest            | 1.0±1.6                              | 0.03±0.09     | 1.6±2.8                         | 0                      | 0.8±1.8                         | 0                |
|                           | VAS palpation          | 5.8±2.9                              | 0.7±0.84      | 5.6±3.3                         | 0.4±0.6                | 6.9±1.4                         | 0.91±0.91        |
|                           |                        | Cryotherapy and Bioptron Light group |               |                                 | Cryotherapy only group |                                 |                  |
|                           |                        | Pre-treatment                        |               | Post-treatment                  |                        | Before treatment                | Post-treatment   |
|                           | VAS pain (0-10)        | 6.66 (6.89–6.46)                     |               | 4.46 (4.62–4.30)                |                        | 6.62 (6.79–6.41) 62.88          | 5.34 (5.48–5.28) |
|                           |                        | Stocking group                       |               |                                 | Tubigrip               |                                 |                  |
| Stasinopoulos et al.[357] |                        | Initial                              |               | 8 weeks                         |                        | Initial                         |                  |
|                           | Total SF-12 score      | 100 (95–105)                         |               | 119 (118–121)                   |                        | 100 (94–107)                    |                  |
|                           | VAS score              | 65 (56–73)                           |               | 5 (0–11)                        |                        | 66 (59–73)                      |                  |
|                           |                        | Standard group                       |               |                                 | Exercise group         |                                 |                  |
| Sultan et al.[378]        |                        | At baseline                          |               | At 1 week                       |                        | At baseline                     |                  |
|                           | LEFS                   | 35.31±16.56                          |               | 54.00±12.61                     |                        | 38.22±19.81                     |                  |
|                           | VAS Pain at rest       | 26.5 (23.3)                          |               | 7.1±7.5                         |                        | 19.6 (17.5)                     |                  |
|                           | VAS Pain with activity | 53.06±27.7                           |               | 34.3±22.9                       |                        | 53.3±22.7                       |                  |
|                           |                        | STG group                            |               | APG group                       |                        |                                 | Mock APG group   |
| Zhao et al.[3940]         |                        | Baseline                             | 8 weeks       | Baseline                        | 8 weeks                | Baseline                        | 8 weeks          |
|                           | VAS pain               | 5.05                                 | 0.26          | 5.05                            | 0.10                   | 4.86                            | 0.41             |
|                           | AOFAS                  | 39.53                                | 97.47         | 38.14                           | 99.04                  | 38.95                           | 96.86            |
|                           | Total SF-12 score      | 107.63                               | 116.21        | 106.14                          | 119.67                 | 104.95                          | 112.05           |

VAS: Visual Analogue Scale; EQ-5D: EuroQol-5D, LLTQ: Lower Limb Task Questionnaire; NPRS: Numerical Pain Rating Scale; SF-12: Short Form-12;  
FAOS: Foot and Ankle Outcome Score; FAAM: Foot and Ankle Ability Measure; LEFS: Lower Extremity Functional Scale.